Clinical Trial Update: Risk of Nocturnal Hypoglycemia and Arrhythmias With Sitagliptin Versus Glimepiride in Patients With Type 2 Diabetes [Phase 4]

View source ↗

Summary

Phase 4 trial comparing risk of nocturnal hypoglycemia and arrhythmias between sitagliptin and glimepiride in type 2 diabetes; terminated with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Glimepiride (glimepiride)
• Sitagliptin (sitagliptin)

Snippet

Sponsor: GWT-TUD GmbH | Conditions: Diabetes Mellitus Type 2 | Phase 4 | Status: TERMINATED | Results posted: 2019-02-27